Author(s): 
Dr Lucas Otieno, MD, Martina Oneko, MD, Walter Otieno, PhD, Joseph Abuodha, MBChB, Emmanuel Owino, MSc, Chris Odero, PGD PH, Yolanda Guerra Mendoza, MD, Ben Andagalu, MSc, Norbert Awino, MSc, Karen Ivinson, BSc, et al.

Please note that you will need to register and login to access the full article for free on TheLancet.com.

Malaria remains a major global public health concern, especially in sub-Saharan Africa. The RTS,S/AS01 malaria candidate vaccine was reviewed by the European Medicines Agency and received a positive scientific opinion; WHO subsequently recommended pilot implementation in sub-Saharan African countries. Because malaria and HIV overlap geographically, HIV-infected children should be considered for RTS,S/AS01 vaccination. We therefore aimed to assess the safety of RTS,S/AS01 in HIV-infected children at two sites in western Kenya.